New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
16:03 EDTKBIOKaloBios presents clinical results from KB002 Phase 1/2 study
KaloBios Pharmaceuticals presented data from its Phase 1/2 study in persistent asthma for KB002, precursor chimeric anti-GM-CSF monoclonal antibody to KB003, at the American Academy of Allergy, Asthma & Immunology Annual Meeting in Austin, Texas. The findings demonstrated preliminary safety, tolerability, and signs of activity of anti- GM-CSF antibodies in asthma and support continued development of the company's Humaneered KB003 anti-GM-CSF monoclonal antibody in severe asthma. KB003 is currently in a Phase 2 trial in severe asthma patients inadequately controlled by corticosteroids. "These initial clinical results with KB002 in asthma are highly encouraging. KB002 was well-tolerated, with no significant adverse events in the study population. When KB002 was added to patients' standard of care treatment, the study also showed a reduction in airway inflammation and improvements in FEV1. Moreover, asthmatics with reversible FEV1 at baseline showed greater FEV1 responses than non-reversible patients. As a result, we are targeting this patient population in our ongoing Phase 2 KB003 study," said chief medical officer Nestor Molfino.
News For KBIO From The Last 14 Days
Check below for free stories on KBIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
09:11 EDTKBIOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
08:02 EDTKBIOKaloBios publication shows EphA3 as target for anticancer therapy
Subscribe for More Information
August 7, 2014
08:05 EDTKBIOKaloBios provides update on clinical programs
Subscribe for More Information
08:02 EDTKBIOKaloBios reports Q2 EPS (30c), consensus (34c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use